Chemistry:EB-003

From HandWiki

EB-003 is a non-hallucinogenic serotonin receptor agonist which is under development for the treatment of depressive disorders and anxiety disorders.[1][2][3][4][5] It is a tryptamine[1][5] and a derivative of the serotonergic psychedelic dimethyltryptamine (DMT).[3]

The drug acts as a non-selective agonist of serotonin receptors, including of the serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptors.[1][3][4][5] It is not a serotonin 5-HT2B receptor agonist.[5][6] EB-003 produces psychoplastogenic effects.[3][4][5] Due to targeting not only the serotonin 5-HT2A receptor but also the serotonin 5-HT1B receptor to influence neuroplasticity, EB-003 has been branded a new type of drug called a "neurostabilogen" by its developer.[3]

EB-003 is being developed by Enveric Biosciences.[1][2] As of February 2025, it is in the preclinical research stage of development.[1][2] A phase 1 clinical trial is being planned.[1] The drug's exact chemical structure does not yet seem to have been disclosed.[1][5] It has been patented, though the patent does not yet appear to have been published.[7]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 "EB-003 - Enveric Biosciences". 6 February 2025. https://adisinsight.springer.com/drugs/800076760. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on EB-003(Enveric Biosciences) with Synapse". 23 January 2025. https://synapse.patsnap.com/drug/c7ebf980608a445fa71a25b0bf2df395. 
  3. ↑ 3.0 3.1 3.2 3.3 3.4 Roberts, Madison (28 August 2025). "AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush?". https://microdose.buzz/news/abbvies-1b-psychedelic-bet-whos-next-in-the-neuroplastogen-gold-rush/. 
  4. ↑ 4.0 4.1 4.2 "Pipeline – Enveric Biosciences". https://www.enveric.com/pipeline/. 
  5. ↑ 5.0 5.1 5.2 5.3 5.4 5.5 "Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series". BusinessWire. 28 December 2023. https://financialpost.com/pmn/business-wire-news-releases-pmn/enveric-biosciences-selects-eb-003-as-lead-drug-candidate-from-evm301-series. 
  6. ↑ "Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003". 15 October 2024. https://www.stocktitan.net/news/ENVB/enveric-biosciences-announces-positive-pharmacology-and-safety-data-reggnmhx6os4.html. 
  7. ↑ "Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office". 30 January 2025. https://finance.yahoo.com/news/enveric-biosciences-receives-notice-allowance-210100668.html. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:EB-003&oldid=4177952"